Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.
about
shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapyExploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesDendritic Cells in Oncolytic Virus-Based Anti-Cancer TherapyTrial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyHIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunityTherapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus.Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy.Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancerOncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.Trial watch: Oncolytic viruses for cancer therapyImmune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Fighting Cancer with Mathematics and Viruses.Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.Decorin-expressing adenovirus decreases collagen synthesis and upregulates MMP expression in keloid fibroblasts and keloid spheroids.Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model.Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development.Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells.Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.Cancer Vaccines in Ovarian Cancer: How Can We Improve?
P2860
Q26765364-754B5802-639B-4C2C-A775-9D45BB768B81Q26772715-D6767665-32E2-415D-9FC7-B79E27BF0F4CQ26774345-6882577E-D537-4131-9564-39B9AE7669AFQ27021951-6378A57D-4BCF-4F97-A45E-0CAB69C5793FQ28072347-7B841605-3E0E-4F01-A069-EE7506E6F5EFQ35108680-AD4E8E56-0525-4AD5-994C-217678505BD5Q35176800-52A7DC0B-FFC9-49C5-9635-89156D2C18C2Q35803316-41512041-81EA-49BF-8D62-4980D0040730Q35878166-AA16FC91-48E1-4D97-A4CB-E850FCE9269DQ36588692-BC0544FD-BF52-46F3-B972-061DCAE35A18Q36664224-33F6D140-9872-43D0-B30A-22DC6F8AE0E1Q36820371-34665B5B-F284-4FA6-A8FE-F4C8ADFE1424Q36981396-A5499CD2-0C62-47DA-937F-2D411791B080Q37028023-A62F780C-78F4-4375-AB0C-2F91725A4CFDQ37211699-01C50E41-ED1C-494E-B8D3-D8A7359FE30FQ37706248-AAD60462-D999-428D-A808-6F1BCA02FD9DQ37709052-985D28DF-B60A-446C-9B26-77C736517FDFQ38002844-C2683270-38C2-4048-87B7-E3FFA572F9D4Q38073096-21471AC5-A3D7-40F4-A3C3-665DBD923012Q38612646-6CA34FF9-56FB-4B77-A2D1-5AC24E55B7ACQ38915884-87F88D8F-44CB-4099-8C39-9B5F91454691Q40438006-1EA37D48-47D7-4C39-BDD2-19BD1B5429C8Q42149285-DFE97E65-6E78-4C0F-9215-651CCB820366Q47135720-32C06B8F-6651-48D3-8F15-5B97DCC54E5DQ47609998-BB421946-F32D-4933-9D69-AA80ECA5F11CQ49805006-389A05FE-A602-45DA-B81E-F33A753F5E1FQ50116283-40062D61-3E08-473E-BA9A-17126AA10EC0Q50566797-D16D9438-9812-4FBC-88C2-3B6E1B3B317CQ54385315-B4D09B2B-15EC-4061-BA41-88329F421105
P2860
Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Optimizing DC vaccination by c ...... coexpressing IL-12 and GM-CSF.
@ast
Optimizing DC vaccination by c ...... coexpressing IL-12 and GM-CSF.
@en
type
label
Optimizing DC vaccination by c ...... coexpressing IL-12 and GM-CSF.
@ast
Optimizing DC vaccination by c ...... coexpressing IL-12 and GM-CSF.
@en
prefLabel
Optimizing DC vaccination by c ...... coexpressing IL-12 and GM-CSF.
@ast
Optimizing DC vaccination by c ...... coexpressing IL-12 and GM-CSF.
@en
P2093
P2860
P356
P1433
P1476
Optimizing DC vaccination by c ...... coexpressing IL-12 and GM-CSF
@en
P2093
Il-Kyu Choi
Ji-Young Yoo
Jing-Hua Huang
Kyung-Ju Choi
Song-Nan Zhang
P2860
P304
P356
10.1038/MT.2011.29
P50
P577
2011-04-05T00:00:00Z